Oppenheimer analyst Mark Breidenbach assigned a Buy rating to ESSA Pharma (EPIX – Research Report) yesterday and set a price
Tag: Mark Breidenbach
Seres Therapeutics (MCRB) Receives a Buy from Oppenheimer
Oppenheimer analyst Mark Breidenbach assigned a Buy rating to Seres Therapeutics (MCRB – Research Report) today and set a price
Oppenheimer Sticks to Their Hold Rating for Agios Pharma (AGIO)
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Hold rating on Agios Pharma (AGIO – Research Report).
ESSA Pharma (EPIX) Receives a Buy from Oppenheimer
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on ESSA Pharma (EPIX – Research Report),
Biolinerx (BLRX) Received its Third Buy in a Row
After Maxim Group and H.C. Wainwright gave Biolinerx (NASDAQ: BLRX) a Buy rating last month, the company received another Buy,
Oppenheimer Keeps a Buy Rating on Gamida Cell (GMDA)
Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Gamida Cell (GMDA – Research Report) yesterday and set a price
What Made Oppenheimer Upgrade Arvinas Holding Company’s Stock?
Oppenheimer analyst Mark Breidenbach upgraded Arvinas Holding Company (ARVN – Research Report) to Buy today and set a price target